Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306743 | 1.00 | PLA2G2A (0.50) | PLA2G2AGAATDP1L3MBTL1BLM | |
| SCHEMBL307515 | 1.00 | PLA2G2A (0.50) | PLA2G2AGAATDP1L3MBTL1BLM | |
| SCHEMBL309333 | 1.00 | PLA2G2A (0.50) | PLA2G2AGAATDP1L3MBTL1BLM | |
| SCHEMBL308232 | 1.00 | PLA2G2A (0.50) | PLA2G2AGAATDP1L3MBTL1BLM | |
| SCHEMBL15298525 | 0.91 | THRB (0.46) | PLA2G2AGAATDP1L3MBTL1BLM | |
| SCHEMBL28360604 | 0.90 | LMNA (0.48) | PLA2G2ABLMNR5A1PLA2G4BTHRA | |
| SCHEMBL9018536 | 0.86 | GAA (0.44) | PLA2G2AGAATDP1L3MBTL1S1PR3 | |
| SCHEMBL13437868 | 0.84 | GAA (0.43) | PLA2G2AGAATDP1L3MBTL1TSHR | |
| SCHEMBL8233545 | 0.83 | L3MBTL1 (0.46) | PLA2G2AGAATDP1L3MBTL1TSHR | |
| SCHEMBL25400967 | 0.83 | THRB (0.50) | PLA2G2ABLMNR5A1TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8092773-B2 | Liquid fullerene derivative, method for producing the same, and device using the same | NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20100019205-A1 | Liquid Fullerene Derivative, Method for Producing the Same, and Device Using the Same | NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100019205-A1 | Liquid Fullerene Derivative, Method for Producing the Same, and Device Using the Same | SCO2, RPLP2, MDM4 | PLA2G2A 2483/4885GAA 4824/4885TDP1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.